News
ABT
105.27
-0.59%
-0.63
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Elevance Health (ELV)
TipRanks · 19h ago
Abbott Labs Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
Abbott Labs Price Target Cut to $125.00/Share From $128.00 by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125
Benzinga · 1d ago
iShares Russell 1000 Value ETF Experiences Big Outflow
NASDAQ · 1d ago
3 Best Stocks to Buy Now, 4/18/2024, According to Top Analysts
TipRanks · 1d ago
Abbott Laboratories First Quarter 2024 Earnings: EPS Beats Expectations
Abbott Laboratories reported strong results for the first quarter of 2024. Earnings per share surpassed analyst estimates by 6.2%. Revenue is forecast to grow 6.3% in the next 3 years. The company's shares are down 4.7% from a week ago. Simply Wall St looks at Abbott Laboratories' balance sheet.
Simply Wall St · 1d ago
ABBOTT LABORATORIES <ABT.N>: RAYMOND JAMES CUTS TARGET PRICE TO $124 FROM $127
Reuters · 1d ago
5 Dividend Aristocrats Where Analysts See Capital Gains
NASDAQ · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)
TipRanks · 1d ago
Buy Rating Affirmed: Abbott Labs Outperforms with Strong Q1 Sales and Upward Earnings Revision
TipRanks · 1d ago
Strong Q1 Performance and Growth Prospects Justify Buy Rating for Abbott Labs
TipRanks · 1d ago
ABBOTT LABORATORIES <ABT.N>: RBC CUTS TARGET PRICE TO $125 FROM $128
Reuters · 1d ago
US STOCKS-Stocks decline as interest rate uncertainty, earnings weigh
U.S. Stocks fall as interest rate uncertainty, earnings weigh United Airlines gains on upbeat Q2 profit forecast. Travelers falls after Q1 profit miss, Prologis drops after disappointing quarterly results. Fed's Beige Book shows slight expansion in economic activity. The S&P 500 is on pace for its fourth straight day of declines.
Reuters · 2d ago
Wednesday Sector Laggards: Healthcare, Technology & Communications
NASDAQ · 2d ago
US STOCKS-S&P 500, Nasdaq dip as interest rate concerns, earnings weigh
U.S. Stocks fall as interest rate concerns, earnings weigh United Airlines gains on upbeat Q2 profit forecast. Travelers falls after Q1 profit miss, Prologis, Abbott Laboratories fall after quarterly results. Dow Jones up 0.03%, S&P 500 off 0.34%, Nasdaq down 0.74%. Travelers tumbled 7.45% after reporting first-quarter results.
Reuters · 2d ago
Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?
The S&P 500 declined by 0.5% in Wednesday's trading session. Bitcoin hit an intraday low of $59,650, down 18% since its peak in March. Investors sought refuge in Treasuries for liquidity, with yields dropping by 8 basis points. The situation in the Middle East remains uncertain.
Benzinga · 2d ago
Noteworthy Wednesday Option Activity: LULU, ABT, AIG
NASDAQ · 2d ago
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
Abbott Laboratories (ABT -2.54%) Q1 2024 Earnings Call to be held on April 17, 2024. Abbott's first-quarter 2024 earnings conference call is being recorded by Abbott. Robert Ford, chairman and chief executive officer of Abbott, will discuss the company's results.
The Motley Fool · 2d ago
Quiver Markets Wrap: S&P 4 Day Losing Streak
Wall Street's main indexes faltered, marking their longest slump since January. The S&P 500 retreated over 4% from its peak. Rising bond yields and a tech sector sell-off led to investor caution. Recent comments by the Federal Reserve Chair Jerome Powell dampened hopes of a rate cut.
Barchart · 2d ago
More
Webull provides a variety of real-time ABT stock news. You can receive the latest news about Abbott Labs through multiple platforms. This information may help you make smarter investment decisions.
About ABT
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.